ArticleCell reports2022
Limited extent and consequences of pancreatic SARS-CoV-2 infection.
Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Risk of incident diabetes post-COVID-19: A systematic review and meta-analysis.Primary care diabetes · 2022Pooled it
- SARS-CoV-2 and diabetes: a post-pandemic reappraisal.Diabetologia · 2026Review
- Impact of SARS-CoV-2 Infection on Diabetic Ketoacidosis in Children with Newly Diagnosed Type-1 Diabetes: A Prospective Multicenter Study.Medeniyet medical journal · 2026Article
- COVID-19 and metabolic health: Lessons from a global pandemic.Metabolism open · 2026Article
- The silent epidemic within the pandemic: pathophysiology and prediction of post-COVID-19 diabetes.Journal of translational medicine · 2026Review
- New insights into the role of metallothioneins in obesity and diabetes.International journal of obesity (2005) · 2025Review
- Pancreatic Injury in Severe SARS-CoV-2 Infection: A Retrospective Study Across Three Pandemic Waves.Life (Basel, Switzerland) · 2025Article
- Increased Incidence of New-Onset Diabetic Retinopathy in Individuals with COVID-19 in an Underserved Urban Population in the Bronx.Diagnostics (Basel, Switzerland) · 2025Article
- SARS-CoV-2 Spike S1 Subunit Triggers Pericyte and Microvascular Dysfunction in Human Pancreatic Islets.Diabetes · 2025Article
- Host factor PLAC8 is required for pancreas infection by SARS-CoV-2.Communications medicine · 2025Article
- Molecular analysis of long COVID and new-onset diabetes mellitus: pathobiological relationships and current mechanistic views.Frontiers in endocrinology · 2025Review
- The relationship between SARS-CoV-2 infection and type 1 diabetes mellitus.Nature reviews. Endocrinology · 2024Review
- Pandemic punch: SARS-CoV-2 hits pancreas.Signal transduction and targeted therapy · 2024Article
- Infection with SARS-CoV-2 can cause pancreatic impairment.Signal transduction and targeted therapy · 2024Article
- Diabetes Mellitus, Energy Metabolism, and COVID-19.Endocrine reviews · 2024Review
- New Insights into the Effects of SARS-CoV-2 on Metabolic Organs: A Narrative Review of COVID-19 Induced Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- New-Onset Diabetes After COVID-19.The Journal of clinical endocrinology and metabolism · 2023Review
- Transcriptional changes in multiple endocrine organs from lethal cases of COVID-19.Journal of molecular medicine (Berlin, Germany) · 2023Article
- The countdown to type 1 diabetes: when, how and why does the clock start?Diabetologia · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 3 institutions in 1 country.
Funding
Abstract
Concerns that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of coronavirus disease 2019 (COVID-19), may cause new-onset diabetes persist in an evolving research landscape, and precise risk assessment is hampered by, at times, conflicting evidence. Here, leveraging comprehensive single-cell analyses of in vitro SARS-CoV-2-infected human pancreatic islets, we demonstrate that productive infection is strictly dependent on the SARS-CoV-2 entry receptor ACE2 and targets practically all pancreatic cell types. Importantly, the infection remains highly circumscribed and largely non-cytopathic and, despite a high viral burden in infected subsets, promotes only modest cellular perturbations and inflammatory responses. Similar experimental outcomes are also observed after islet infection with endemic coronaviruses. Thus, the limits of pancreatic SARS-CoV-2 infection, even under in vitro conditions of enhanced virus exposure, challenge the proposition that in vivo targeting of β cells by SARS-CoV-2 precipitates new-onset diabetes. Whether restricted pancreatic damage and immunological alterations accrued by COVID-19 increase cumulative diabetes risk, however, remains to be evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.